“Also, the relationship with FDA is exceedingly sensitive - anything that comes across as "shaming" or pressuring is not helpful.”

You make a great point here. IMO, posting on this message board about the FDA process and how leronlimab has traversed that process is fine. What I don’t think is ok is asking questions during CCs or web conferences about the FDA process (complaints), emailing NP about the FDA process (complaints) or complaining about the FDA process in emails to individuals or entities when trying to inform them about leronlimab. The CC last week and the web conference on Friday were filled with repeat questions, questions answered during the initial part of the event, and with questions about other drugs and the FDA. Those shouldn’t be answered and clearly were upsetting NP and I don’t blame him.

IMO, emails and communication about leronlimab to reporters, politicians and medical professions should contain a short, concise message about leronlimab that outlines the facts to date. Any mention, IMO, of how the FDA has ignored leronlimab, or how BP suppresses leronlimab, etc., discredits the entire message.